Cardiovascular complications in COVID-19 patients
Keywords:
SARS-CoV-2, COVID-19, cardiovascular complications.Abstract
Introduction: The COVID-19 typically presents as a lower respiratory tract infection. Among its various extrapulmonary manifestations is cardiovascular damage, and these are the ones that are most associated with morbidity and mortality. A search for scientific information was carried; resources were obtained from databases PubMed, PubMed Central, SciELO, Ebsco, ClinicalKey, and Scopus. The search strategies formulated were: SARS-CoV-2, COVID-19, Cardiovascular complications; as well as its translations into the English language.Objective: To describe the cardiovascular complications in patients with the COVID-19.
Development: There is a wide diversity of criteria in the scientific literature regarding cardiovascular damage in the context of COVID-19 infection. Frequently reported cardiovascular complications are acute myocardial injury, acute myocarditis, cardiac arrhythmias, acute coronary syndrome, acute heart failure, heart valve damage, venous thromboembolic disease, and shock.
Conclusions: Cardiovascular complications in COVID-19 carriers were described. SARS-CoV-2 infection causes direct or indirect damage to the myocardium, heart valves and the rest of the cardiovascular system.
Downloads
Download data is not yet available.
References
1. Ena J, Wenzel RP. Un nuevo coronavirus emerge. Rev Clin Esp; 2020. [acceso: 15/09/2020];220(2):115-6. Disponible en: https://doi.org/10.1016/j.rce.2020.01.001
2. Guo YR, Cao QD, Hong ZS. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res; 2020. [acceso: 15/09/2020];7:1-10. Disponible en: https://dx.doi.org/10.1186/s40779-020-00240-0
3. Hijona-Elósegui JJ. Nuevas evidencias que descartan la posible transmisión vertical del SARS-CoV-2 durante la gestación. Med Clin; 2020. [acceso:15/09/2020];155(7):313-14. Disponible en: https://doi.org/10.1016/j.medcli.2020.05.021
4. Ferreira MJ, Irigoyen MC, Consolim-Colombo F, Kerr-Saraiva JF, De Angelis K. Vida Fisicamente Ativa como Medida de Enfrentamentoao COVID-19. Arq Bras Cardiol; 2020. [acceso:15/09/2020];114(4):601-2. Disponible en: https://doi.org/10.36660/abc.20200235
5. Díaz-Jiménez IV. Interpretación de las pruebas diagnósticas del virus SARS-CoV-2. Acta Pediatr Méx; 2020. [acceso:15/09/2020];41(1):51-7. Disponible en: https://www.medigraphic.com/pdfs/actpedmex/apm-2020/apms201h.pdf
6. Zhao G. Tomar medidas preventivas inmediatamente: evidencia de China sobre el COVID-19. Gac Sanit; 2020. [acceso: 15/09/2020];34(3):217-9. Disponible en: https://doi.org/10.1016/j.gaceta.2020.03.002
7. Espinosa-Rosales FJ. Inmunopatología de la infección por virus SARS-CoV-2. Acta Pediatr Méx; 2020. [acceso:15/09/2020];41(1):42-50. Disponible en: https://www.medigraphic.com/pdfs/actpedmex/apm-2020/apms201g.pdf
8. Llor C, Moragas A. Coronavirus y atención primaria. Aten Primaria; 2020. [acceso: 15/09/2020];52(5):294-6. Disponible en: https://doi.org/10.1016/j.aprim.2020.03.002
9. Hulot JS. COVID-19 in patients with cardiovascular diseases. Archives of Cardiovascular Disease; 2020. [acceso:15/09/2020];113(4):225-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32245656/
10. Pallarés-Carratalá V, Górriz-Zambrano C, Morillas-Ariño C, Llisterri-Caro JL, Gorriz JL. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos? Semergen; 2020. [acceso:15/09/2020];46(S1):85-94. Disponible en: https://doi.org/10.1016/j.semerg.2020.05.005
11. Gupta MD, Girish MP, Yadav G, Shanker A, Yadav R. Coronavirus Disease 2019 and Cardiovascular System: Impacts and Implications. Indian Heart Journal; 2020. [acceso: 15/09/2020];2(1):1-6. Disponible en: https://doi.org/10.1016/j.ihj.2020.03.006
12. Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundo. Vacunas; 2020. [acceso:15/09/2020];21(1):17-22. Disponible en: https://doi.org/10.1016/j.vacun.2020.03.001
13. Sánchez-Tauma PJ, Atamari-Anahui N, Valera-Moreno C. Enfermedad por Coronavirus 2019, COVID-19: Aspectos a considerar en niños. Rev. cuerpo méd. HNAAA; 2020. [acceso:15/09/2020];13(1):88-95. Disponible en: https://doi.org/10.35434/rcmhnaaa.2020.131.629
14. Shetty AK. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19) - Induced Pneumonia. Aging and Disease; 2020. [acceso: 15/09/2020];11(2):462-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32257554/
15. Borges F, Sparano A, Hermanni M, Marcano E. COVID-19 y corazón en Pediatría. Archivos Venezolanos de Puericultura y Pediatría; 2020. [acceso:15/09/2020];83(2):18-24. Disponible en: https://intelego-eu.com/wp-content/uploads/2020/06/AVPP-Sup-2-Consenso-Vzlano-sobre-manifestaciones-sistemicas-de-ls-COVID-19.pdf
16. Percy E, Luc JGY, Vervoort D, Hirji S, Ruel M, Coutinho T. Post-Discharge Cardiac Care in the Era of Coronavirus 2019: How Should We Prepare? Canadian Journal of Cardiology; 2020. [acceso:15/09/2020];36(6):956-60. Disponible en: https://www.sciencedirect.com/science/article/pii/S0828282X20303883?via%3Dihub
17. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology; 2020. [acceso:15/09/2020];17(5):259-60. Disponible en: https://doi.org/10.1038/s41569-020-0360-5
18. Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol; 2020. [acceso:15/09/2020];109(5):531-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32161990/
19. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology; 2020. [acceso:15/09/2020]; 309:70-77. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32248966/
20. Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med; 2020. [acceso:15/09/2020];20:19-21. Disponible en: https://doi.org/10.1016/S2213-2600(20)30076-X
21. Moreno-Martínez FL, Moreno-López FL, Oroz-Moreno R. Repercusión cardiovascular de la infección por el nuevo coronavirus SARS-CoV-2 (COVID-19). CorSalud; 2020. [acceso:15/09/2020];12(1):3-17. Disponible en: https://www.revcorsalud.sld.cu/index.php/cors/article/view/588
22. Thakkar AN, Tea I, Al-Mallah MH. Cardiovascular Implications of COVID-19 Infections. Methodist Debakey Cardiovasc J; 2020. [acceso:15/09/2020];16(2):146-55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350814/
23. Bansal M. Cardiovascular disease and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews; 2020. [acceso:15/09/2020]; 14:247-250. Disponible en: https://doi.org/10.1016/j.dsx.2020.03.013
24. Chen D, Li X, Song Q, Hu C, Su F, Dai J. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). Med Rxiv [preprint]; 2020. [acceso: 15/09/2020]: [aprox. 20 p.]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.27.20028530v1.full.pdf+html
25. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med; 2018. [acceso:15/09/2020];378(4):345-53. Disponible en: https://doi.org/10.1056/NEJMc1805679
26. Pavón-Rojas AJ, Escalona-González SO, Cisnero-Reyes L. Mecanismos fisiopatogénicos involucrados en el daño cardiovascular en pacientes portadores de COVID-19. Revista Ciencias Médicas de Pinar del Río; 2020. [acceso: 15/09/2020];24(5):e4482. Disponible en: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/4482
27. Figueroa-Triana JF, Salas-Márquez DA, Cabrera-Silva JA, Alvarado-Castro CC, Buitrago-Sandoval AF. COVID-19 y enfermedad cardiovascular. Rev Colomb Cardiol; 2020. [acceso:15/09/2020];27(3):166-174. Disponible en: https://doi.org/10.1016/j.rccar.2020.04.004
28. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet; 2020. [acceso: 15/09/2020];395(10229):1054-1062. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32171076/
29. Prasad A, Panhwar S, Hendel RC, Sheikh O. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J; 2020. [acceso:15/09/2020];226:174-187. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32599258/
30. Davis GK, Adlan A, Majewski J, Ibrahim B. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know. Clinical Medicine; 2020. [acceso: 15/09/2020];20(3):262-265. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354031/
31. Li X, Yu S. Cardiac valves: Another "Disaster-hit area" of COVID-19 patients? Heart & Lung; 2020. [acceso: 15/09/2020];49(6):890-891. Disponible en: https://doi.org/10.1016/j.hrtlng.2020.05.004
32. Driggin E, Madhavan MV, Bikdeli B, Chuich T. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. Journal of the American College of Cardiology; 2020. [acceso: 15/09/2020];75(18):2352-71. Disponible en: https://doi.org/10.1016/j.jacc.2020.03.031
33. Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost; 2020. [acceso:15/09/2020];18(4):844-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32073213/
34. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA; 2020. [acceso:15/09/2020];323(11):1061-9. Disponible en: https://doi.org/10.1001/jama.2020.1585
35. Clemente-Herrera A, Sánchez-De la Torre EJ, Enríquez-Contreras JM. Manifestaciones cardiológicas en pacientes con COVID-19. MedInt Méx; 2020. [acceso: 15/09/2020];36(3):357-64. Disponible en: https://doi.org/10.24245/mim.v36i3.4229
2. Guo YR, Cao QD, Hong ZS. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res; 2020. [acceso: 15/09/2020];7:1-10. Disponible en: https://dx.doi.org/10.1186/s40779-020-00240-0
3. Hijona-Elósegui JJ. Nuevas evidencias que descartan la posible transmisión vertical del SARS-CoV-2 durante la gestación. Med Clin; 2020. [acceso:15/09/2020];155(7):313-14. Disponible en: https://doi.org/10.1016/j.medcli.2020.05.021
4. Ferreira MJ, Irigoyen MC, Consolim-Colombo F, Kerr-Saraiva JF, De Angelis K. Vida Fisicamente Ativa como Medida de Enfrentamentoao COVID-19. Arq Bras Cardiol; 2020. [acceso:15/09/2020];114(4):601-2. Disponible en: https://doi.org/10.36660/abc.20200235
5. Díaz-Jiménez IV. Interpretación de las pruebas diagnósticas del virus SARS-CoV-2. Acta Pediatr Méx; 2020. [acceso:15/09/2020];41(1):51-7. Disponible en: https://www.medigraphic.com/pdfs/actpedmex/apm-2020/apms201h.pdf
6. Zhao G. Tomar medidas preventivas inmediatamente: evidencia de China sobre el COVID-19. Gac Sanit; 2020. [acceso: 15/09/2020];34(3):217-9. Disponible en: https://doi.org/10.1016/j.gaceta.2020.03.002
7. Espinosa-Rosales FJ. Inmunopatología de la infección por virus SARS-CoV-2. Acta Pediatr Méx; 2020. [acceso:15/09/2020];41(1):42-50. Disponible en: https://www.medigraphic.com/pdfs/actpedmex/apm-2020/apms201g.pdf
8. Llor C, Moragas A. Coronavirus y atención primaria. Aten Primaria; 2020. [acceso: 15/09/2020];52(5):294-6. Disponible en: https://doi.org/10.1016/j.aprim.2020.03.002
9. Hulot JS. COVID-19 in patients with cardiovascular diseases. Archives of Cardiovascular Disease; 2020. [acceso:15/09/2020];113(4):225-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32245656/
10. Pallarés-Carratalá V, Górriz-Zambrano C, Morillas-Ariño C, Llisterri-Caro JL, Gorriz JL. COVID-19 y enfermedad cardiovascular y renal: ¿Dónde estamos? ¿Hacia dónde vamos? Semergen; 2020. [acceso:15/09/2020];46(S1):85-94. Disponible en: https://doi.org/10.1016/j.semerg.2020.05.005
11. Gupta MD, Girish MP, Yadav G, Shanker A, Yadav R. Coronavirus Disease 2019 and Cardiovascular System: Impacts and Implications. Indian Heart Journal; 2020. [acceso: 15/09/2020];2(1):1-6. Disponible en: https://doi.org/10.1016/j.ihj.2020.03.006
12. Reina J. El SARS-CoV-2, una nueva zoonosis pandémica que amenaza al mundo. Vacunas; 2020. [acceso:15/09/2020];21(1):17-22. Disponible en: https://doi.org/10.1016/j.vacun.2020.03.001
13. Sánchez-Tauma PJ, Atamari-Anahui N, Valera-Moreno C. Enfermedad por Coronavirus 2019, COVID-19: Aspectos a considerar en niños. Rev. cuerpo méd. HNAAA; 2020. [acceso:15/09/2020];13(1):88-95. Disponible en: https://doi.org/10.35434/rcmhnaaa.2020.131.629
14. Shetty AK. Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19) - Induced Pneumonia. Aging and Disease; 2020. [acceso: 15/09/2020];11(2):462-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32257554/
15. Borges F, Sparano A, Hermanni M, Marcano E. COVID-19 y corazón en Pediatría. Archivos Venezolanos de Puericultura y Pediatría; 2020. [acceso:15/09/2020];83(2):18-24. Disponible en: https://intelego-eu.com/wp-content/uploads/2020/06/AVPP-Sup-2-Consenso-Vzlano-sobre-manifestaciones-sistemicas-de-ls-COVID-19.pdf
16. Percy E, Luc JGY, Vervoort D, Hirji S, Ruel M, Coutinho T. Post-Discharge Cardiac Care in the Era of Coronavirus 2019: How Should We Prepare? Canadian Journal of Cardiology; 2020. [acceso:15/09/2020];36(6):956-60. Disponible en: https://www.sciencedirect.com/science/article/pii/S0828282X20303883?via%3Dihub
17. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology; 2020. [acceso:15/09/2020];17(5):259-60. Disponible en: https://doi.org/10.1038/s41569-020-0360-5
18. Li B, Yang J, Zhao F. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol; 2020. [acceso:15/09/2020];109(5):531-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32161990/
19. Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. International Journal of Cardiology; 2020. [acceso:15/09/2020]; 309:70-77. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32248966/
20. Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med; 2020. [acceso:15/09/2020];20:19-21. Disponible en: https://doi.org/10.1016/S2213-2600(20)30076-X
21. Moreno-Martínez FL, Moreno-López FL, Oroz-Moreno R. Repercusión cardiovascular de la infección por el nuevo coronavirus SARS-CoV-2 (COVID-19). CorSalud; 2020. [acceso:15/09/2020];12(1):3-17. Disponible en: https://www.revcorsalud.sld.cu/index.php/cors/article/view/588
22. Thakkar AN, Tea I, Al-Mallah MH. Cardiovascular Implications of COVID-19 Infections. Methodist Debakey Cardiovasc J; 2020. [acceso:15/09/2020];16(2):146-55. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350814/
23. Bansal M. Cardiovascular disease and COVID-19. Diabetes & Metabolic Syndrome: Clinical Research & Reviews; 2020. [acceso:15/09/2020]; 14:247-250. Disponible en: https://doi.org/10.1016/j.dsx.2020.03.013
24. Chen D, Li X, Song Q, Hu C, Su F, Dai J. Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19). Med Rxiv [preprint]; 2020. [acceso: 15/09/2020]: [aprox. 20 p.]. Disponible en: https://www.medrxiv.org/content/10.1101/2020.02.27.20028530v1.full.pdf+html
25. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med; 2018. [acceso:15/09/2020];378(4):345-53. Disponible en: https://doi.org/10.1056/NEJMc1805679
26. Pavón-Rojas AJ, Escalona-González SO, Cisnero-Reyes L. Mecanismos fisiopatogénicos involucrados en el daño cardiovascular en pacientes portadores de COVID-19. Revista Ciencias Médicas de Pinar del Río; 2020. [acceso: 15/09/2020];24(5):e4482. Disponible en: https://revcmpinar.sld.cu/index.php/publicaciones/article/view/4482
27. Figueroa-Triana JF, Salas-Márquez DA, Cabrera-Silva JA, Alvarado-Castro CC, Buitrago-Sandoval AF. COVID-19 y enfermedad cardiovascular. Rev Colomb Cardiol; 2020. [acceso:15/09/2020];27(3):166-174. Disponible en: https://doi.org/10.1016/j.rccar.2020.04.004
28. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet; 2020. [acceso: 15/09/2020];395(10229):1054-1062. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32171076/
29. Prasad A, Panhwar S, Hendel RC, Sheikh O. COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. Am Heart J; 2020. [acceso:15/09/2020];226:174-187. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32599258/
30. Davis GK, Adlan A, Majewski J, Ibrahim B. SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know. Clinical Medicine; 2020. [acceso: 15/09/2020];20(3):262-265. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354031/
31. Li X, Yu S. Cardiac valves: Another "Disaster-hit area" of COVID-19 patients? Heart & Lung; 2020. [acceso: 15/09/2020];49(6):890-891. Disponible en: https://doi.org/10.1016/j.hrtlng.2020.05.004
32. Driggin E, Madhavan MV, Bikdeli B, Chuich T. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. Journal of the American College of Cardiology; 2020. [acceso: 15/09/2020];75(18):2352-71. Disponible en: https://doi.org/10.1016/j.jacc.2020.03.031
33. Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost; 2020. [acceso:15/09/2020];18(4):844-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32073213/
34. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA; 2020. [acceso:15/09/2020];323(11):1061-9. Disponible en: https://doi.org/10.1001/jama.2020.1585
35. Clemente-Herrera A, Sánchez-De la Torre EJ, Enríquez-Contreras JM. Manifestaciones cardiológicas en pacientes con COVID-19. MedInt Méx; 2020. [acceso: 15/09/2020];36(3):357-64. Disponible en: https://doi.org/10.24245/mim.v36i3.4229
Published
2021-07-01
How to Cite
1.
Pavon-Rojas AJ, Cisnero-Reyes L, Escalona-González SO, Rojas-Silva O, Pérez-Pérez CJ. Cardiovascular complications in COVID-19 patients. Rev Cubana Med Milit [Internet]. 2021 Jul. 1 [cited 2025 Apr. 2];50(3):e02101145. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/1145
Issue
Section
Review Article
License
Authors who have publications with this Journal accept the following terms:
- The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
- The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
- Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.
